Exenatide Effects on Glycemic Control in Type 2 Diabetes
Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metform
Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin - Endocrine Practice
Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes | Diabetes Technology & Therapeutics
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes | Cardiovascular Diabetology | Full Text
Overview of clinical trials comparing liraglutide qd with exenatide... | Download Table
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art - ScienceDirect
ADA: Efficacy and Safety of Lixisenatide Once-Daily vs. Exenatide Twice-Daily in Type 2 DM Inadequately Controlled on Metformin (GetGoal-X)
GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Cla
Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin- exenatide study | BMC
Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis - ScienceDirect
Mean direct medical cost (€) per patient receiving exenatide bid or... | Download Table
DATA SHEET
The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial | Nature Communications
Abstract 13242: Risk of Cardiovascular Events in Patients with Type 2 Diabetes Treated With Exenatide BID or Other Glucose-Lowering Therapies: A Retrospective Analysis of the LifeLinkTM Database | Circulation
Comparison between twice-daily (BID) exenatide (10 mg) and once-daily... | Download Scientific Diagram
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes | Cardiovascular Diabetology | Full Text
Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial | Scientific Reports
Liraglutide Versus Exenatide Once Weekly_ Persistence, Adherence, and Early Discontinuation
![exenatide [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1.png?w=600&tok=baf39c "exenatide [TUSOM | Pharmwiki]")
exenatide [TUSOM | Pharmwiki]
Liraglutide Achieves A1C Targets More often than Sitagliptin or Exenatide when Added to Metformin in Patients with Type 2 Diabetes and a Baseline A1C <8.0% - Endocrine Practice
Efficacy and Safety of Exenatide versus Insulin in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis
MTF Formulary Management for the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs)
A1C Data | BYDUREON BCise® (exenatide extended-release) injectable suspension 2 mg | For HCPs
